MBX Biosciences Phase 1 data supports once-monthly dosing for MBX 4291

MBX Biosciences (MBX) announced multiple updates on its obesity portfolio, including preliminary blinded Phase 1 data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity, which demonstrate a pharmacokinetic profile supporting the potential for once-monthly dosing and competitive weight loss in the first multiple ascending dose cohort. “The unique pharmacokinetic profile of MBX 4291 has the potential to support a self-titrating weekly induction regimen and the potential for true once-monthly dosing,” said Sam Azoulay, chief medical officer of MBX Biosciences. “Moreover, preliminary blinded data from the first MAD cohort following four weekly titration doses and a single once-monthly dose demonstrated gradual accumulation of active peptide, leading to competitive weight loss and tolerability after eight weeks.”